| Literature DB >> 36043252 |
Dae-Hoon Lee1, Ja-In Seo1, Seung-Il Song1, Jeong-Keun Lee1.
Abstract
Objectives: There have been few studies to date on the residual effect of bisphosphonate. This study investigated the radiographic changes of mandibular cortical thickness upon bisphosphonate drug holiday. Materials andEntities:
Keywords: Bisphosphonate holidays; Bisphosphonate-associated osteonecrosis of the jaw; Panoramic radiography
Year: 2022 PMID: 36043252 PMCID: PMC9433857 DOI: 10.5125/jkaoms.2022.48.4.219
Source DB: PubMed Journal: J Korean Assoc Oral Maxillofac Surg ISSN: 1225-1585
Patient demographics
| No. | Sex | Age (yr) | Drug type | Indication | Follow-up duration (mo) |
|---|---|---|---|---|---|
| 1 | F | 83 | Alendronate | Osteoporosis | 24 |
| 2 | F | 77 | Risedronate | Osteoporosis | 14 |
| 3 | F | 65 | Alendronate | Osteoporosis | 60 |
| 4 | F | 70 | Alendronate | Osteoporosis | 12 |
| 5 | F | 63 | Unknown type | Osteoporosis | 15 |
| 6 | F | 78 | Unknown type | Osteoporosis | 12 |
| 7 | F | 85 | Risedronate | Osteoporosis | 12 |
| 8 | F | 64 | Alendronate | Osteoporosis | 71 |
| 9 | F | 60 | Zoledronate | Bone tumor | 19 |
| 10 | F | 72 | Ibandronate | Osteoporosis | 12 |
| 11 | F | 73 | Alendronate | Osteoporosis | 24 |
| 12 | F | 74 | Risedronate | Osteoporosis | 24 |
| 13 | F | 73 | Alendronate | Osteoporosis | 12 |
| 14 | F | 79 | Unknown type | Osteoporosis | 52 |
| 15 | F | 87 | Ibandronate | Osteoporosis | 12 |
| 16 | M | 65 | Alendronate | Osteoporosis | 14 |
| 17 | F | 75 | Ibandronate | Osteoporosis | 28 |
| 18 | F | 78 | Alendronate | Osteoporosis | 12 |
| 19 | F | 87 | Alendronate | Osteoporosis | 13 |
| 20 | F | 87 | Zoledronate | Osteoporosis | 16 |
| 21 | F | 88 | Ibandronate | Osteoporosis | 12 |
| 22 | F | 70 | Risedronate and ibandronate | Osteoporosis | 24 |
| 23 | F | 69 | Ibandronate | Osteoporosis | 28 |
| 24 | F | 69 | Unknown type | Osteoporosis | 13 |
| 25 | F | 76 | Unknown type | Osteoporosis | 12 |
| 26 | F | 90 | Unknown type | Osteoporosis | 15 |
| 27 | F | 77 | Unknown type | Osteoporosis | 36 |
| 28 | F | 74 | Alendronate | Osteoporosis | 12 |
| 29 | F | 81 | Pamidronate | Bone tumor | 12 |
| 30 | M | 77 | Alendronate | Osteoporosis | 12 |
| 31 | F | 66 | Risedronate | Osteoporosis | 20 |
| 32 | F | 82 | Unknown type | Osteoporosis | 22 |
| 33 | F | 87 | Alendronate | Osteoporosis | 21 |
| 34 | F | 83 | Risedronate and denosumab | Osteoporosis | 12 |
| 35 | F | 70 | Risedronate | Osteoporosis | 17 |
| 36 | M | 41 | Zoledronate | Bone tumor | 28 |
(F: female, M: male)
Fig. 1Defining landmarks by Ledgerton’s method. Panoramic mandibular index (PMI) and mental index (MI), S=the distance from the superior border of mental foramen to mandibular border, I=the distance from the inferior border to mandibular border, C=cortical bone thickness, that is MI.
Fig. 2Groups of patients according to drug holiday length. When comparing T0 and T1, the size of group was 24, patients of which have taken dental panoramic radiograph at starting point of drug discontinuation and 12 months from the start. When comparing T0 and T2, the size of group was 13, patients of which have taken the radiograph at starting point of drug discontinuation and 18-24 months from the start.
Fig. 3Comparison of index values. MI=mental index, PMI(I and S)=panoramic mandibular index. When comparing T0 and T1, the size of the group was 24. When comparing T1 and T2, the size of the group was 13.
Mean measurement values and P-value of comparison, PMI(I)
| Group size | T0 | T1 | T2 | |
|---|---|---|---|---|
| n=24 | 0.191 | 0.190 | - | 0.683 |
| n=13 | 0.209 | - | 0.182 | 0.007 |
(T0: at the starting point of discontinuation, T1: 12 months after discontinuation, T2: 18 months after discontinuation)
Mean measurement values and P-value of comparison, PMI(S)
| Group size | T0 | T1 | T2 | |
|---|---|---|---|---|
| n=24 | 0.157 | 0.156 | - | 0.740 |
| n=13 | 0.173 | - | 0.152 | 0.006 |
(T0: at the starting point of discontinuation, T1: 12 months after discontinuation, T2: 18 months after discontinuation)
Mean measurement values and P-value of comparison, MI (unit: mm)
| Group size | T0 | T1 | T2 | |
|---|---|---|---|---|
| n=24 | 2.54 | 2.47 | - | 0.299 |
| n=13 | 2.77 | - | 2.42 | 0.003 |
(T0: at the starting point of discontinuation, T1: 12 months after discontinuation, T2: 18 months after discontinuation)
Intra-rater reliability evaluation
| I | S | C | |
|---|---|---|---|
| ICC (3,1) | 0.994 | 0.995 | 0.993 |
| Pearson correlation | 0.990 | 0.991 | 0.988 |
(I: the distance from the inferior borber of mental foramen to mandibular border, S: the distance from the superior border of mental foramen to mandibular border, C: cortical bone thickness)